Drugs / 608
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06222671 | Mar 2024 → Sep 2025 overdue | spondyloarthropathy | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 608 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06222671 ↗ |
| Route | Subcutaneous | “608 subcutaneous (SC) injection.” NCT06222671 ↗ |